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Myasthenia gravis is of particular interest to anaesthetists because of the muscle groups aﬀected, the pharmacology of the
neuromuscular junction, and interaction of both the disease and treatment with many anaesthetic drugs. Anaesthetists may
encounter children with myasthenia either to facilitate treatment options or to institute mechanical ventilation in the face of a
crisis. This paper reviews the literature pertaining to the pathophysiology and applied pharmacology of the disease and explores
the relationship between these and the anaesthetic management. In addition to illustrating the tried-and-tested techniques, some
newer management options are explored.
1.Introduction
Myasthenia gravis (MG) is an autoimmune disease of the
neuromuscular junction characterised by weakness and
fatiguability of skeletal muscles. It can present signiﬁcant
challenges to the anaesthetist, not only because of the nature
of the disease itself but also because of the treatment that
patients may be on and the interaction of these treatments
with many anaesthetic drugs.
MG aﬀects children in three main forms—juvenile,
neonatal, and congenital. Juvenile is the commonest form of
the disease representing 10–15% of all cases of myasthenia
in both children and younger adults [1]. It is caused by IgG
autoantibodies which are directed towards the acetylcholine
receptors on the postsynaptic membrane of the neuromus-
cular junction. This causes both a decrease in receptor
numbers as well as a conformational change in the motor
endplate, resulting in fewer synaptic folds and a wider syn-
aptic cleft [2]. As a consequence, the usual physiological
excess of acetyl choline is deranged and a nerve action
potential may not result in muscular contraction. In juvenile
MG the thymus gland is often hyperplastic, and although
the exact relationship between the gland and the disease
remains obscure, certain patients are known to beneﬁt from
thymectomy [3, 4].
Neonatal MG aﬀects 10% of babies born to mothers
suﬀering from MG and is caused by the placental transfer
of maternal antiacetylcholine receptor antibodies. Recovery
tends to occur spontaneously within about 6 weeks. In
some cases mechanical ventilation and treatment with anti-
cholinesterases may be required [5].
CongenitalMGisarareheterogeneousdiseasewhichcan
aﬀect the whole neuromuscular junction. It is classiﬁed into
presynaptic,synaptic,andpostsynapticforms,andtreatment
and clinical picture depend on the subtype [6]. Owing to its
rarity and the fact that anaesthetic experience is extremely
limited,weshallnotconsideritfurther.Inthispaperweshall
concentrate on the juvenile form of the disease as this is the
form which is most likely to be encountered by anaesthetists.
Anaesthetic management depends upon sound under-
standing ofthepathophysiology ofthe diseaseprocessaswell
as the pharmacology of the neuromuscular junction.
2.ClinicalPicture
The clinical picture is one of weakness and fatiguability
of skeletal muscles. A common presentation is of ocular
weaknessresultinginptosis,diplopia,orvariablestrabismus.
Presentation is however variable and may involve ocular
signs, generalised weakness, or a combination [7–10]. Bulbar
weakness is often a prominent feature and may result in
feeding diﬃculties as well as dysarthria. Respiratory muscles
are aﬀected in about 20% of myasthenic patients though
rarely in isolation [5]. Myasthenic crises (see below) may2 Autoimmune Diseases
occur during times of physiological stress such as infection,
surgery, or heightened emotion and result in an acute
deterioration in muscle strength necessitating mechanical
ventilation [11].
3.Diagnosis
Conﬁrmation of a diagnosis involves 3 tests [11–13].
Administration of edrophonium—a short acting acetyl-
cholinesterase inhibitor—inhibits the breakdown of acetyl-
choline at the neuromuscular junction (NMJ). Thus, the
physiological excess of acetylcholine is restored. The test, if
positive, results in a rapid improvement in muscle strength
which occurs after about 30s and lasts for about 5 minutes.
This is often known as the Tensilon test. Antibodies to the
acetylcholine receptor itself can be detected in the blood
of certain individuals with MG. The test is highly speciﬁc
and becomes increasingly sensitive with increasing age and
increasing duration of disease such that about 56% of
prepubertal children and up to 82% of peripubertal children
with juvenile MG will have detectable antibodies against the
acetylcholine receptor [14]. Single ﬁbre EMG is a deﬁnitive
way of elucidating neuromuscular transmission disorders
but is not speciﬁc for MG and may well not be tolerated in
children [15].
4. Treatment
There are 2 main approaches to the treatment of children
with myasthenia gravis [16]. The ﬁrst strategy is to pharma-
cologically enhance the amount of acetylcholine at the NMJ.
Thesecondstrategyistomodulatetheimmunesystem.Most
patients require elements of both.
Acetylcholinesterase inhibitors work by inhibiting the
actions of acetylcholinesterase—an enzyme present at the
NMJ which breaks down acetylcholine. During a normal
muscular contraction, acetylcholine released from the presy-
naptic terminal diﬀuses across the NMJ combining with
acetylcholine receptors on the motor endplate. Conforma-
tional change of the receptor causes inﬂux of sodium ions
resulting in depolarisation, release of calcium from the
sarcoplasmic reticulum, and subsequent muscular contrac-
tion. Acetylcholine at the NMJ is broken down by acetyl-
cholinesterase thus terminating its actions and allowing for
closure of sodium channels and subsequent repolarisation
of the motor end plate. Acetylcholinesterase inhibitors work
by inhibiting the breakdown of acetylcholine meaning that
more is available to facilitate muscular contraction. They
can be categorised according to their duration of action.
Edrophonium (see above) is a short-acting drug, useful in
diagnosis but too short acting to be useful in treatment.
Of the longer-acting agents, pyridostigmine is generally
preferred as it has a longer duration of action and less
muscarinic side eﬀects than neostigmine [7]. Most patients
will respond well to administration of acetylcholinesterase
inhibitors.
Second-line treatment involves administration of corti-
costeroidsinanattempttomodulatetheimmunesystemand
consequently reduce the serum level of antibodies against
the acetylcholine receptor. If used, they are generally used
in relatively large doses carrying the risk of signiﬁcant
side eﬀects—all of which are well documented in children
[15]. Other immunomodulatory drugs such as cyclosporine,
azathioprine, and cyclophosphamide are rarely used, due to
their signiﬁcant side-eﬀect proﬁle and limited experience in
the paediatric setting.
In the event of an acute deterioration administration of
immunoglobulins (IVIGs) or plasma exchange may help to
stave oﬀ mechanical ventilation [15, 17]. Of the two, plasma
exchange is the more eﬀective but also the more laborious to
perform, requiring large bore central venous access. For this
reason, administration of immunoglobulins is generally the
preferred ﬁrst-line approach, with plasmapheresis available
for the more serious cases.
The thymus gland is implicated in a high proportion of
children with juvenile MG. Thymectomy has been shown to
bring about improvement in symptoms in between 60–90%
of patients undergoing the procedure [9, 15]. The eﬀects of
thymectomy may take a period of months or even years to
bring about such improvements. The procedure is generally
performed when children are at least 10 years old [18]. If
performed too early the chances of remission are higher
and there are theoretical concerns regarding removal of the
thymus gland at a period when the immune system is still
developing.
5.Crises
Myasthenic patients can suﬀer an acute deterioration in their
neuromuscular function sometimes necessitating mechan-
ical ventilation. These episodes are known as crises and
take two main forms—myasthenic and cholinergic [11].
A myasthenic crisis is brought about by a relative decrease
in the amount of acetylcholine at the NMJ resulting in
muscular weakness. It may be precipitated by stress, surgery,
or infection, and treatment depends on the administration
of anticholinesterases or in more severe cases IVIG or plasma
exchange transfusion.
Cholinergic crisis is brought about by excessive admin-
istration of acetylcholinesterase inhibitors resulting in an
excess of Ach at the motor end plate. In addition to muscular
weakness, the child may also demonstrate other cholinergic
signs such as sweating, salivation, diarrhea and blurred
vision. Treatment is based upon withholding administration
of further acetylcholinesterase inhibitors and supportive
measures.
The two crises are diﬃcult to distinguish from each other
clinically but can be diﬀerentiated by the administration of
edrophonium. This will bring about an improvement in a
myastheniccrisisbutworsenacholinergicone[7].Evidently,
full resuscitative equipment must be on hand prior to its
administration.
6. Pharmacological Considerations
SpeciﬁctoAnaesthesia
6.1. Neuromuscular Blocking Agents. Myasthenic patients
have a variable response to muscle relaxants dependingAutoimmune Diseases 3
on the type of muscle relaxant used. Decreased density of
Ach receptors at the motor end plate means that paediatric
myasthenic patients may require up to 4 times the calculated
dose of suxamethonium in order to bring about a depo-
larising muscle block [7]. In addition, suxamethonium is
metabolised by acetylcholinesterase, and as a result, treat-
ment with acetylcholinesterase inhibitors causes a reduction
in its metabolism and a prolongation of its action [19]. For
thisreasonsuxamethoniumshouldbeavoidedinmyasthenic
patients.
The nondepolarising muscle relaxants on the other hand
have a signiﬁcantly enhanced activity as well as a signiﬁ-
cantly prolonged duration of action [20]. Unfortunately, the
degree to which sensitivity is increased is unpredictable and
depends on interaction between disease severity and eﬃcacy
of treatment [7, 21–23]. In adults, the most extensively
studied muscle relaxants are atracurium and vecuronium. In
children, Brown recommended atracurium as the relaxant
of choice, due to its metabolism which has been shown to
be noncumulative [7]. Rocuronium has been shown to be
safe in adults with myasthenia gravis [24], and there are also
several reports of its actions being successfully terminated
by the administration of sugammadex [25, 26]. Sugam-
madex negates the need to administer acetylcholinesterase
inhibitors to reverse residual neuromuscular blockade and
does not carry the associated risks of precipitating a cholin-
ergic crisis. To date, the authors are unaware of any reports
in the literature highlighting the use of either rocuronium or
sugammadex in paediatric myasthenic patients.
6.2. Anaesthetic Agents. Volatile anaesthetic agents are
already known to inhibit neuromuscular transmission, and
these eﬀects are thought to be exaggerated in myasthenic
patients[27–32].However,noclinicallysigniﬁcantpostoper-
ative neuromuscular depression has ever been demonstrated
withisoﬂurane,sevoﬂurane,ordesﬂurane[27,32,33].These
neuromuscular deﬁcits are not a feature of propofol, making
total intravenous anaesthesia (TIVA); theoretically at least,
the technique of choice for these patients [29].
Remifentanil is metabolised by nonspeciﬁc esterases, and
as a result, concern has been expressed regarding a pro-
longed duration of action in patients treated with acetyl-
cholinesterase inhibitors [34]. This however has not been
shown to be the case. Similarly, plasma exchange transfusion
is thought to decrease the concentration of plasma esterases.
Prolongation in the clearance of remifentanil has how-
ever never been demonstrated following plasma exchange
transfusion—possibly as it is metabolised to a signiﬁcant
extent by tissue esterases [35].
6.3. Anticholinesterases. As already mentioned these drugs
bring about a signiﬁcant prolongation of the duration of
action of suxamethonium (and also mivacurium by the same
action [36]). In addition, patients receiving preoperative
treatment with anticholinesterases may show a decreased
response to the administration of neostigmine intraoper-
atively [12]. This may make reversal of residual neuro-
muscular blockade even more challenging. Furthermore,
intraoperative administration may precipitate cholinergic
crisis, potentially confusing the issue of the patient with
postoperative weakness.
7. Anaesthetic Management
Anaesthetists may become involved in the management of
these children for several reasons. Patients may suﬀer a crisis
necessitating institution of mechanical ventilation or the
siting of large-bore central venous access to facilitate plasma
exchangetransfusion.Theymayrequirethymectomy,orthey
may require surgery unrelated to their myasthenia—either
in an elective or an emergency situation. Below are some of
the general principles that apply to the management of these
children, with further detail pertaining to those requiring
thymectomy at the end.
7.1. Preoperative. Severity of weakness and muscle groups
aﬀected should be carefully noted and documented with
particular focus on respiratory and bulbar function. Respira-
tory function tests may be useful in determining the degree
of respiratory involvement and the likely requirement for
post-operative ventilation. In children, these are frequently
not possible, irrespective of whether in the elective or
emergency setting. For elective surgery, pre-perative con-
sultation with the child’s neurologist should be sought,
in order to optimise treatment. Thorough preoperative
assessment and pre-optimisation has been shown to improve
the frequency of post-operative complications [37]. In the
case of severe weakness, pre-operative administration of
IVIG or even exchange transfusion may be required to
improve neuromuscular function. The child should be
placed ﬁrst on the morning list and have their morning
dose of anticholinesterases omitted [38]. The exception
to this may be the child with severe weakness who may
require continuation of this treatment in order to prevent a
signiﬁcant deterioration.
Clearly in the emergency setting, these are luxuries
that one is unlikely to be able to aﬀord. Nevertheless,
due consideration should be given towards the level of
pre-optimisation that may be achievable within the time
constraints imposed by the urgency of surgery.
7.2. Anaesthetic Technique. Technique will be inﬂuenced sig-
niﬁcantly by the extent and nature of planned surgery,
whether emergency or elective and whether there is risk of
a full stomach. For all but the most minor surgery in the
stable myasthenic without signiﬁcant respiratory or bulbar
compromise, an endotracheal tube and intermittent positive
pressureventilationarelikelytoberequired.Ifpossible,intu-
bation of the trachea should be performed without the use
of muscle relaxants. In the paediatric setting, this is already
well described and used frequently. Tracheal intubation with
volatiles alone or following an iv induction with propofol
and a short-acting opioid are well described in myasthenic
children[39–42].Theuseofpropofolandremifentanilinthe
form of target-controlled infusion (TCI) is well described in
adult myasthenics [43, 44]. TIVA without TCI has also been
described in the paediatric literature, but until more recently4 Autoimmune Diseases
pump technology has not allowed this technique to be used
successfully in children under the age of 16 years [35, 45]. It
will be interesting to see whether reports of its use appear in
the literature over coming years.
If muscle relaxants are used, they should be used in
smaller doses and should always be used in conjunction with
eﬀective neuromuscular monitoring [38]. This should be in
the form of a nerve stimulator with an accurate, objective
assessment of muscle response such as acceleromyography,
mechanomyography, or electromyography.
Children on high-dose corticosteroids will require sup-
plementation in the perioperative period [13].
The situation of the myasthenic patient requiring rapid
sequence induction because of full stomach is a diﬃcult one.
Suxamethonium should be avoided because of the reasons
already mentioned. Although rocuronium could theoreti-
cally be used, determining the dose to give is more diﬃ-
cult. Sugammadex has been used to reverse neuromuscular
blockade following administration of 0.5mg·kg−1, but there
is no experience of its use following the higher dose required
for rapid sequence induction [26]. Intravenous induction
with propofol (3mg·kg−1), remifentanil (1.25mcg·kg−1)
and lidocaine (1.5mg·kg−1) has been described in a 14-year-
old girl requiring rapid sequence induction because of a full
stomach [46]. It should be noted that this patient had severe
preexisting neuromuscular dysfunction, though the authors
noted that excellent intubating conditions were obtained
after 60 seconds. There are no other reports in the literature
of rapid sequence induction of either adult or paediatric
patients.
7.3. Postoperative Considerations. Planning for the post-
operative period requires meticulous communication be-
tween surgeon, anaesthetist, neurologist, and intensivist.
Even following a minor procedure in a stable patient, a
period of close observation in the recovery area is required to
ensure that neuromuscular function—especially pertaining
to respiratory and bulbar function—has returned to the pre-
operative state. Accordingly, the more extensive the surgery,
the greater the duration of procedure, and the greater
the exposure to drugs that interfere with neuromuscular
function, the more important this period becomes. Those at
risk of signiﬁcant reduction in neuromuscular function, or
those who have signiﬁcant respiratory or bulbar impairment
preoperatively, may require observation on an intensive
care unit. Postoperative ventilation, assuming reasonable
respiratory function preoperatively, is rarely required even
following extensive surgery [13, 47].
In the event of a signiﬁcant deterioration in neuro-
muscular function postoperatively, attention needs to be
given towards ascertaining whether one is dealing with a
myasthenic or cholinergic crisis. Cholinergic crisis, even if
acetylcholinesterase inhibitors have been administered at the
end of the procedure, is very rare. If there is any doubt as to
the exact nature, edrophonium as opposed to neostigmine
should be used due to the rapid onset and oﬀset. Provision
shouldalwaysbemadeforelectivereintubationifrespiratory
function is deemed inadequate.
7.4. Thymectomy. Thymectomy can be performed via an
open sternotomy or via a thoracoscopic approach. Thoraco-
scopic thymectomy is associated with less chest wall trauma
and may be associated with lower post-operative morbidity
and shorter hospital stay [12, 48]. Surgery itself, however,
may be prolonged, and because the mediastinum is accessed
via the chest wall, selective one-lung ventilation required.
Commonly, the right lung is isolated. A variety of meth-
ods have been used, including endobronchial intubation,
bronchial blocker, double lumen endotracheal tube, and
standard endotracheal tube with carbon dioxide insuﬄation
of the left hemithorax [48]. The potential haemodynamic
consequences of such techniques and the eﬀects on gas
exchange necessitate invasive arterial monitoring.
Analgesia is another important issue in these patients—
especially those undergoing open sternotomy. Epidural anal-
gesia has been described in adult myasthenics undergoing
median sternotomy [49]. The requirement for high thoracic
block has often deterred paediatric anaesthetists from using
this technique due to the possibility of haemodynamic
compromise (hypotension and bradycardia) and respiratory
embarrassment. More recently, reports have appeared in the
literature of using high thoracic epidural to great eﬀect—
providing post-operative analgesia without any haemody-
namic or respiratory compromise [45]. In cases where
epidural analgesia is not used, remifentanil infusion intra-
operatively followed by administration of a longer-acting
opioid towards the end of the procedure and PCA has been
described [38].
Patients should be extubated as soon as possible at the
end of the procedure to reduce the incidence of respiratory
complications. Prolonged invasive ventilation is associated
with greater respiratory morbidity [50]. If the patient is
usually taking anticholinesterases but has omitted them on
the morning of surgery, a dose of neostigmine is likely to
be required towards the end of surgery. Anticholinesterases
should be continued in the post-operative period, and dose
should be titrated towards eﬀect. Corticosteroids can be
weaned down with a view towards stopping [38].
8. Conclusions
In this paper we have presented some of the main issues
pertaining to the anaesthetist in the management of the
child with juvenile MG. We have looked at the underlying
pathophysiology of the disease process and how this relates
to the applied pharmacology of drugs aﬀecting the neu-
romuscular junction. We have examined the controversial
issue of neuromuscular blocking drugs and explored some of
the alternatives to their use. These alternatives often render
neuromuscular blocking agents obsolete. In addition, the
role of TIVA as the anaesthetic of choice has been explored,
and we look forward to hearing about its use in conjunction
with TCI more frequently in the future as experience with
newer pump technology continues to grow. Finally, we have
examined some of the key points in the management of
patients presenting for thymectomy.
Optimal management of any child with myasthenia
gravis, irrespective of surgery performed, requires a soundAutoimmune Diseases 5
understanding of disease pathophysiology and pharmacol-
ogy, meticulous planning, and close consultation between
surgeon, anaesthetist, and neurologist.
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